Angiotensin 1 7

This is the first book addressing in full the most important aspects of the angiotensin-(1-7), the key peptide of the protective axis and the main component in the new modulatory concept of the renin-angiotensin system. It features a detailed review of angiotensin-(1-7) and its receptor Mas, comprising the historical background, enzymatic pathways for generation, functions, integrative aspects of its protective profile, and its therapeutic potential. It also encompasses a comprehensive presentation of current knowledge about its widespread biological actions on several tissues, as well as the most recent scientific achievements, emerging from preclinical and clinical trials. Dr. Santos is a renowned researcher on the Renin-Angiontensin system, with remarkable achievements regarding the role of peptides such as alamandine and angiontensin-(1-7). He has also worked on the potential clinical applicability of angiotensin-(1-7)-related drugs for cardiovascular diseases. He has an extensive publication record in the field, including the publication of the book The Protective Arm of the Renin Angiotensin System (Academic Press, 2015). Angiotensin-(1-7) will make a unique contribution to the literature and will be an important resource for biomedical students and researchers, medical practitioners and any other professional interested in this peptide and its role in the renin-angiotensin system.

This is the first book addressing in full the most important aspects of the angiotensin-(1-7), the key peptide of the protective axis and the main component in the new modulatory concept of the renin-angiotensin system. It features a detailed review of angiotensin-(1-7) and its receptor Mas, comprising the historical background, enzymatic pathways for generation, functions, integrative aspects of its protective profile, and its therapeutic potential. It also encompasses a comprehensive presentation of current knowledge about its widespread biological actions on several tissues, as well as the most recent scientific achievements, emerging from preclinical and clinical trials. Dr. Santos is a renowned researcher on the Renin-Angiontensin system, with remarkable achievements regarding the role of peptides such as alamandine and angiontensin-(1-7). He has also worked on the potential clinical applicability of angiotensin-(1-7)-related drugs for cardiovascular diseases. He has an extensive publication record in the field, including the publication of the book The Protective Arm of the Renin Angiotensin System (Academic Press, 2015). Angiotensin-(1-7) will make a unique contribution to the literature and will be an important resource for biomedical students and researchers, medical practitioners and any other professional interested in this peptide and its role in the renin-angiotensin system.

The Protective Arm of the Renin Angiotensin System: Functional Aspects and Therapeutic Implications is the first comprehensive publication to signal the protective role of a distinct part of the renin–angiotensin system (RAS), providing readers with early insight into a complex system which will become of major medical importance in the near future. Focusing on recent research, The Protective Arm of the Renin Angiotensin System presents a host of new experimental studies on specific components of the RAS, namely angiotensin AT2 receptors (AT2R), the angiotensin (1–7) peptide with its receptor Mas, and the enzyme ACE 2, which exert significant beneficial, health-promoting actions by counterbalancing the well-known harmful arm of the RAS with its classical angiotensin AT1 receptor. This innovative concept of the protective arm of the RAS, examined in this reference, represents an indispensable background and will be a strong support for biomedical students, researchers, cardiologists, surgeons, nephrologists, diabetologists, and endocrinologists, as well as any other physician or researcher concerned with RAS physiology, pathophysiology and clinical implications. Provides a complete understanding of the protective side of the Renin Angiotensin System (RAS) involving angiotensin AT2 receptor, ACE2, and Ang(1-7)/Mas receptor Combines the knowledge of editors who pioneered research on the protective renin angiotensin system including; Dr. Thomas Unger, one of the founders of AT2 receptor research; Dr. Ulrike M. Steckelings, who contributed significantly to first preclinical studies with a novel specific AT2-agonist, and Dr. Robson Santos who pioneered research on angiotensin-(1-7) and its receptor Mas. Shows that the protective RAS axes are able to ameliorate the course of several cardiovascular, renal, metabolic and neurological diseases Provides the basis for the understanding of a novel therapeutic approach to stimulate components of the protective arm of the RAS.

This book of the series on “Advances in Biochemistry in Health and Disease” includes state-of-the-art information on the status of renin-angiotensin system (RAS) in the form of 24 chapters. This book has been organized into three sections: (i) General Implications of RAS in human health and Infectious Diseases, (ii) Lung, Liver and Kidney Diseases, and (iii) Development of Cancer. Each chapter has discussed comprehensive knowledge regarding the molecular and cellular aspects of the role of RAS in the pathophysiology and pharmacotherapy of different disease processes. Biochemical mechanisms associated with angiotensin II type 1 and type II receptors, and angiotensin (1-7) MAS receptors for the occurrence of both harmful and beneficial effects of prolonged activation of RAS in different diseases have been outlined. It is noteworthy to point out that different chapter in this book were prepared by recognized global expertise in the area of inflammation, oxidative stress and signal transduction pathways to highlight the role of RAS in different diseases. It is our sincere hope that this book will be of great interest to both biomedical investigators and health professionals as well as graduate students and postdoctoral fellows all over the world.

This book offers the latest research into the role of the renin angiotensin system on cardiac and vascular functions and in cardiovascular diseases. It covers vital aspects such as intracellular signaling and regulation of cell volume in the failing heart.

The renin-angiotensin system (RAS) is one of the most important endocrine (tissue-to-tissue), paracrine (cell-to-cell) and intracrine (intracellular/nuclear) humoral systems in the regulation of blood pressure, cardiovascular, and kidney function in health and disease. The RAS has remarkably evolved from the initial discovery of the rate-limiting enzyme renin to a complex biochemical and physiological cascade involving more than a dozen members. Currently, there are up to five axes or pathways identified in the RAS; each has its substrate, enzyme, effector peptide, receptor, and downstream signaling pathways. These include the renin/ACE/ANG II/AT1 receptor, the APA/ANG III/AT2 receptor, the ACE2/ANG (1-7)/Mas receptor, the prorenin/prorenin receptor (PRR), and the ANG IV/AT4 receptor (IRAP) pathways. Accordingly, the roles of the RAS have expanded well beyond the classic endocrine paradigm as a powerful vasoconstrictor, a potent aldosterone stimulator, or a sodium-retaining hormonal system. The goals of this article are to review and discuss the current insights into and new perspectives on the expression, localization, and novel actions of the RAS with a focus in the kidney. Special emphasis will be placed on recently discovered new members of the RAS derived from studies using innovative mutant rats or mice that either overexpress (knockin) or are deficient (knockout) of a particular substrate, enzyme, ANG peptide, or receptor. This new knowledge will help improve our understanding how each of these pathways act directly or indirectly to regulate blood pressure, cardiovascular and kidney function in physiology, and can be targeted to treat hypertension, cardiovascular and renal diseases.

Significant Pharmaceuticals Reported in US Patents identifies the next generation of pharmaceuticals reported in US Patents. This "hands-on" title provides explicit laboratory methods for preparing the most recent and effective medications. Each entry documents the biological testing protocols used to evaluate a drug and the significance of the current treatment agent over previous methods. Pharmaceuticals are included in this review only if at least two of the following criteria were met: Effectiveness in treating an illness, Innovative, ease of preparation, synergy with existing Medications. Pharmaceuticals are reported for 27 separate classes of illness, including: AIDS, Alzheimer's Disease, Cardiovascular Disorders, Diabetes, Epilepsy, Hepatitis C, Osteoporosis, Obesity and Sleep Disorders. Significant Pharmaceuticals Reported in US Patents has been designed to be used as both a reference and synthetic guide for pharmaceutical, medicinal and organic chemists and graduate students. Researchers working in other areas will also find the information valuable as in many instances intermediates or the next generation pharmaceutical are readily convertible into other industrial products including: anti-oxidants, chemical additives, herbicides, polymer precursors, water purification agents. Clear structural depictions of reagents and chemical transformations have been supplied to permit the identification of other future applications. Identifies next generation pharmaceuticals Provides practical preparation methods for each active agent and derivatives Documents the analytical characterization and biological testing results of active agents

Early Vascular Aging (EVA): New Directions in Cardiovascular Protection, Second Edition continues to be the most comprehensive and authoritative resource on premature alterations in artery structure and function. The book presents a novel approach to the problem of cardiovascular disease, showing it in relation to great vessels disease and revealing a comprehensive approach to the problem of increased rigidity of the great vessels, its causes, and further consequences. This second edition contains completely updated content with expanded coverage of basic and translational research, systematic reviews of the most prominent literature, discussion of applicability of new evidence and more. Written by an international team of clinicians and researchers, this is a valuable resource to basic and translational scientists, clinical researchers and clinicians in the cardiovascular field interested in prevention, diagnosis and treatment of EVA. Contains all the relevant information available on the main paradigm shifts in vascular aging research, from different fields of knowledge (from basic biology to epidemiology) Reviews the most prominent evidence produced on early vascular aging (EVA), highlighting recent research advances, clinical applications, and research opportunities Formulates, in each chapter, a set of research questions that need to be addressed, challenging the vast research community to take on new directions and collaborations